Immutep (ASX:IMM) said its first-in-human phase 1 trial showed a favorable safety profile of its lead drug candidate IMP761 being developed for various autoimmune diseases, according to a Tuesday filing with the Australian bourse.

Results from the first three of a five single-dose ascending study showed no adverse events, with pharmacokinetic and pharmacodynamic relationship report slated for release in the first half of next year, the filing said.

The company's shares were down nearly 3% in recent Tuesday trade.

Price (AUD): $0.33, Change: $-0.01, Percent Change: -2.94%